RxDoctor Payments DataLook up a doctor →

Christopher Dankmyer, MD

Physical Medicine & Rehabilitation · Pottstown, PANPI 1801810247

Payments from drug & device makers

$7,273in general payments, 2019–2025

Across 306 payments — averaging $23.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$814
  • AbbVie$728
  • Scilex Pharmaceuticals Inc.$627
  • Collegium Pharmaceutical, Inc.$585
  • Averitas Pharma Inc.$471
  • MDD US Operations, LLC$319
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$7,273100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,273 in reported general payments places this provider in the 90th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.

See all physical medicine & rehabilitation providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$376,589
Medicare patients
524
Services billed
12,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina17$24,365
Xtampza ErOxycodone Myristate11$7,250
Ms ContinMorphine Sulfate12$5,558
Gabapentin140$1,132
Celecoxib22$703
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen25$460
Tizanidine Hcl60$428
Nabumetone34$306
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen26$247
Tramadol Hcl50$231
Meloxicam35$85
Duloxetine Hcl11$44
Methylprednisolone11$37
Diazepam27$17

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$728$24,36517 claims
Collegium Pharmaceutical, Inc.Xtampza Er$585$7,25011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.

Other physical medicine & rehabilitation in Pottstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →